Sinem Kocagil

Dr. Sinem Kocagil


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
MÇMüge Çınar
Müge Çınar
GYGonca Kılıç Yıldırım
Gonca Kılıç Yıldırım
SKSinem Kocagil
Sinem Kocagil
OÇOğuz Çilingir
Oğuz Çilingir
Objectives: The aim of our study was to define the genotype–phenotype correlations of mutations in the PAH gene among the Turkey’s Central Anatolian region. Methods: Demographic characteristics of 108 patients with hyperphenylalaninemia (HPA) and 94 patients whose diagnosis was confirmed by PAH gene analysis (Sanger DNA Sequence Analysis and Next-Generation Sequencing) were determined retrospectively. Blood phenylalanine levels were analyzed using the high-performance liquid chromatography method. Results: Mild HPA-not-requiring-treatment (NT) was found in 50.9% of the patients, and a classical phenylketonuria (PKU) phenotype was found in 25.9%. Forty-seven types of variants were identified. The predominant variants were p.Ala403Val (9.9%), p.Ala300Ser (9.4%), and c.1066-11G>A (splicing) (9.4%). Missense mutations accounted for 68% of mutations and attenuated the clinical impact; splice variations were found in 14.8% of cases with severe features. The p.Thr380Met allele was specific to the mild HPA-NT group. The c.1066-11G>A (splicing) allele was associated with classical PKU, whereas the p.Arg408Trp allele was linked to severe symptoms. Three variations of unknown clinical significance were discovered: c.706+4A>T (splicing), c.843-5T>C (splicing), and p.Thr323=. Of these variants, the patient who was homozygous for the c.843-5T>C (splicing) allele related to the classical PKU phenotype. 70% of the patients who underwent tetrahydrobiopterin (BH4) test were responsive. Phenotypes that responded to BH4 treatment were mostly mild phenotypes. Conclusions: The PAH genotype is the main factor that determines the phenotype of PKU. Establishing the relationship between the identified genetic mutations and phenotypic characteristics will provide very important data for each patient in terms of the specific management style.

31 May 2024 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
EŞEnver Şimşek
Enver Şimşek
OÇOğuz Çilingir
Oğuz Çilingir
TŞTülay Şimşek
Tülay Şimşek
SKSinem Kocagil
Sinem Kocagil
EGEbru Erzurumluoğlu Gökalp
Ebru Erzurumluoğlu Gökalp
ÇBÇiğdem Binay
Çiğdem Binay
Maturity-onset diabetes of the young (MODY) is the most common type of monogenic diabetes. To date, mutations have been identified in 14 different genes of patients with a clinical diagnosis of MODY. This study screened mutations in 14 MODY-related genes and the regulator factor X6 (RFX6) gene in children. The presence of clinical features of MODY and negative results for three autoantibody markers of T1DM in children and adolescents were used as inclusion criteria for genetic testing. The screening panel for next-generation sequencing included 14 MODY-related genes (GCK, HNF4A, HNF1A, HNF1B, PDX1, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8, KCNJ11, and APPL1) and the RFX6 gene. Twenty-four different variants in MODY-related genes were identified in 49 children diagnosed with autoantibody-negative type 1 diabetes mellitus (T1DM). A 12 variants were classified as P/LP while 12 were interpreted as variant of unknown significance (VUS). Nine of the pathogenic or likely pathogenic variants were found in GCK, two in HNF1B, and one in ABCC8. Three variants were novel, and one was a de novo variant. All of the variants, except one, showed heterozygotic inheritance. This study screened mutations in the 14 MODY-related genes and the regulatory factor X6 (RFX6) gene in Turkish children diagnosed with autoantibody-negative type 1 diabetes mellitus (T1DM). The frequencies of the MODY subtypes differed from previous reports. Although GCK-MODY was the most frequent mutation in Turkish children, similar to previous studies, the second most prevalent MODY subtype was HNF1B-MODY. This study also established three additional novel mutations in different MODY genes.

4 July 2025 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
ASAbdullah Sezer
Abdullah Sezer
SOSukru S. Oner
Sukru S. Oner
HSHanife Saat
Hanife Saat
MTMerve G. Turan
Merve G. Turan
TGTulin Gungor
Tulin Gungor
OKOktay I. Kaplan
Oktay I. Kaplan
Cranioectodermal dysplasia (CED) is a ciliopathy characterized by skeletal and ectodermal abnormalities, renal failure, and liver fibrosis. Pathogenic variants in genes that encode the intraflagellar transport (IFT) complex components, particularly IFT-A, are responsible for approximately two-thirds of the CED cases. However, the cause of the remaining cases remains unknown. Ciliogenesis-associated kinase 1 (CILK1) is a highly conserved ciliary serine/threonine kinase with an N-terminal catalytic domain responsible for kinase activity and a C-terminal non-catalytic domain that interacts with the IFT-B complex. Biallelic variants in the catalytic domain are associated with lethal skeletal dysplasia, endocrine cerebroosteodysplasia, and short-rib polydactyly syndrome. No human disease has been linked to biallelic variants in the non-catalytic domain. We present a homozygous frameshift variant in the CILK1 gene that affects the distal part of the non-catalytic domain, causing CED in five patients from two pedigrees. All the patients survived into childhood and had disproportionately short stature, skeletal abnormalities, ectodermal dysplasia, renal issues, and liver complications. Functional data from patient-derived cells and the C. elegans model indicate that the variant reduces cilia number, increases cilia length, and disrupts the localization of IFT components. In contrast, the ciliary localization of CILK1 bearing the variant itself remains unaffected. Notably, we rescued the majority of these abnormalities by reintroducing CILK1 into patient-derived cells. Finally, our study describes CILK1 as a novel causal gene and the first non-IFT protein-encoding gene in the etiology of CED, thus expanding the known genotypic, mechanistic, and phenotypic spectrum of CED.

1 October 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
SASevilhan Artan
Sevilhan Artan
EGEbru Erzurumluoglu Gokalp
Ebru Erzurumluoglu Gokalp
BSBedia Samanci
Bedia Samanci
DADemet Ozbabalik Adapinar
Demet Ozbabalik Adapinar
HBHasan Bas
Hasan Bas
MEMurat Emre
Murat Emre

25 September 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
HBHasan Bas
Hasan Bas
SSSuzan Saylisoy
Suzan Saylisoy
OCOguz Cilingir
Oguz Cilingir
EGEbru Erzurumluoglu Gokalp
Ebru Erzurumluoglu Gokalp
SKSinem Kocagil
Sinem Kocagil
SASevilhan Artan
Sevilhan Artan

15 December 2021 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
SISevgi Işık
Sevgi Işık
GGGulcin Gunden
Gulcin Gunden
EGEren Gunduz
Eren Gunduz
OAOlga Meltem Akay
Olga Meltem Akay
AAAbdulvahap Aslan
Abdulvahap Aslan
BABeyhan Durak Aras
Beyhan Durak Aras
Deletion 13q [del(13q)] is a favorable prognostic marker if it is detected as a sole abnormality in chronic lymphocytic leukemia (CLL). However the clinical courses of cases with isolated del(13q) are quite heterogeneous. In our study, we investigated copy number variations (CNVs), loss of heterozygosity (LOH), and the size of del(13q) in 30 CLL patients with isolated del(13q). We used CGH+SNP microarrays in order to understand the cause of this clinical heterogeneity. We detected del(13q) in 28/30 CLL cases. The size of the deletion varied from 0.34 to 28.81 Mb, and there was no clinical effect of the deletion size. We found new prognostic markers, especially the gain of 16p13.3. These markers have statistically significant associations with short time to first treatment and advanced disease stage. Detecting both CNVs and LOH at the same time is an advantageous feature of aCGH+SNP. However, it is very challenging for the array analysis to detect mosaic anomalies. Therefore, it is very important to confirm the results by FISH. In our study, we detected approximately 9% mosaic del(13q) by microarray. In addition, the gain of 16p13.3 may affect the disease prognosis in CLL. However, additional studies with more patients are needed to confirm these results.